From: Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1
Patient characteristics | n = 59 |
---|---|
Age, years | Â |
 Median | 69 |
 Range | 47–86 |
Sex, n (%) | Â |
 Male | 50 (84.7) |
 Female | 9 (15.3) |
Histology, n (%) | Â |
 Adeno | 26 (44.1) |
 Squamous | 16 (27.1) |
 NOS | 17 (28.8) |
Smoking history, n (%) | Â |
 Current or former smoker | 52 (88.1) |
 Never smoked | 7 (11.9) |
Disease stage, n (%) | Â |
 C-stage IIIB | 5 (8.5) |
 C-stage IV | 41 (69.5) |
 Recurrence | 13 (22.0) |
PD-L1 TPS, n (%) | Â |
 50% or greater | 57 (96.6) |
 1–49% | 2 (3.4) |
Best response, n (%) | Â |
 CR or PR | 21 (35.6) |
 SD | 17 (28.8) |
 PD | 12 (20.3) |
 NE | 9 (15.3) |